Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03737370
Recruitment Status : Recruiting
First Posted : November 9, 2018
Last Update Posted : February 1, 2021
Sponsor:
Collaborators:
Bayer
Lahey Clinic
Henry Ford Hospital
Ohio State University Comprehensive Cancer Center
Information provided by (Responsible Party):
Tufts Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : October 31, 2022
Publications: